


07/28/03



UTILITY PATENT APPLICATION

Attorney Docket No.

P50165-1C6

TRANSMITTAL

First Named Inventor

Barnette et al.

of new nonprovisional applications under 37 CFR 1.53(b))

"EXPRESS MAIL CERTIFICATE"

EXPRESS MAIL MAILING LABEL NUMBER EV332944659US

DATE OF DEPOSIT: 28 JULY 2003

I hereby certify that this paper or fee and the papers indicated as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date and with the Mailing Label Number indicated above and addressed to: COMMISSIONER FOR PATENTS, MAIL STOP: PATENT APPLICATION, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT) STEVEN DLSZEWSKI

SIGNATURE

22241 U.S. PTO
10/628655

07/28/03

APPLICATION ELEMENTS	
See MPEP chapter 600 concerning utility patent application contents.	
1. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge indicated fees and credit any overpayments to Deposit Account No. 19-2570 <input checked="" type="checkbox"/> General Authorization to charge any and all fees under 37 CFR 1.16 or 1.17, including petitions for extensions of time, relating to this application. (37 CFR 1.136(a)(3)) (Submit an original, and a duplicate for fee processing)	7. <input checked="" type="checkbox"/> The Title of the Invention: COMPOUNDS
2. <input checked="" type="checkbox"/> The total fee is calculated as shown below: Basic Filing fee \$750.00 Total Claims 4 - 20 = 0 x \$18 \$ 0.00 Independent Claims 3 - 3 = 0 x \$84 \$ 0.00 <input type="checkbox"/> Multiple Dependent Claim present. \$280 TOTAL FILING FEE \$750.00 <input type="checkbox"/> Cancel in this application original claims to of the prior application before calculating the filing fee. <input checked="" type="checkbox"/> Charge \$750.00 to the above indicated Deposit Account.	8. <input type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission a. <input type="checkbox"/> Computer Readable Copy b. <input type="checkbox"/> Paper Copy (identical to computer copy) c. <input type="checkbox"/> Statement verifying identity of above copies d. <input type="checkbox"/> Use the identical computer-readable form filed in Application No. , filed as the computer-readable form for the instant application. (37 CFR 1.821(e))
3a. <input checked="" type="checkbox"/> Specification excluding Drawings [Total Pages] 16 3b. <input checked="" type="checkbox"/> Abstract on a separate sheet [Total Pages] 1	9. ACCOMPANYING APPLICATION PARTS a. <input type="checkbox"/> Information Disclosure Statement (IDS) b. <input type="checkbox"/> PTO-1449 c. <input checked="" type="checkbox"/> Copies of all IDS Citations (3 sheets)
4. <input type="checkbox"/> Drawing(s) (35 USC 113) [Total Sheets]	10. <input type="checkbox"/> Assignment Papers (cover sheet & document(s))
5. <input checked="" type="checkbox"/> Declaration and Power of Attorney [Total Pages] 3 a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17a completed) c. <input type="checkbox"/> Unsigned Declaration [Note Box 6 below] i. <input type="checkbox"/> DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).	11. <input checked="" type="checkbox"/> Prior Application is Assigned to: SmithKline Beecham Corporation (for continuation/divisional with Box 17a completed)
6. <input checked="" type="checkbox"/> Incorporation By Reference (useable if Box 5b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 5b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.	12. <input type="checkbox"/> Preliminary Amendment [Total Pages]
17. <input type="checkbox"/> Priority Information, check appropriate box and supply the requisite information	13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)
a. The accompanying application is a <input checked="" type="checkbox"/> Continuation <input type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior Application No. 09/452,654 filed 01 December 1999 which is a continuation of Application Serial No. 08/944,044 filed 03 March 1997, which issued on 07 December 1999 as U.S. Patent No. 5,998,428, which is a continuation of Application No. 08/456,274, filed 21 May 1995, which issued on 07 November 2000 as U.S. Patent No. 6,143,782, which is a continuation of PCT/US94/06861 filed 17 June 1994 which claims priority from Application No. 08/080,377 filed 21 June 1993, which is a continuation-in-part of Application No. 08/080,034 filed 18 June 1993.	14. <input type="checkbox"/> Certified Copy of Priority Document(s) (if foreign priority is claimed)
b. <input type="checkbox"/> Benefit is claimed under Title 35, United States Code, Section 119(e) of the following Provisional Applications: Application No. filed	15. <input checked="" type="checkbox"/> Transfer all references cited by Applicants or by the Examiner from the parent Application Serial No. 09/452,654 filed 01 December 1999. A PTO-1449 listing the references is enclosed.
c. <input checked="" type="checkbox"/> Please amend the specification by inserting before the first line the sentence: (37 CFR 1.78) This is a continuation of application Serial No. 09/452,654 filed December 1, 1999.	16. <input checked="" type="checkbox"/> Other: Abstract
Correspondence Address: GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Telephone (610) 270-5014 Fax (610) 270-5090	Respectfully Submitted, JAMES M. KANAGY Registration No. 29,550

20462

PATENT TRADEMARK OFFICE